Health · Pharma & Biotech · 1 hr ago

Usona’s reported psilocybin filing reshapes forecasts for Compass drug

Usona’s reported psilocybin filing reshapes forecasts for Compass drug

Usona Institute may have filed for FDA approval of its psilocybin treatment for major depressive disorder, though the Wisconsin nonprofit has not confirmed the submission.

Usona began a Phase 3 trial in 2024 and received an FDA voucher for faster review, but it has not publicly released the trial results.

Compass Pathways has completed its application for COMP360, a psilocybin treatment for treatment-resistant depression.

The two drugs target different forms of depression, and Usona says its mission is to provide psilocybin at low cost, while Compass is expected to price its patented drug like a branded medicine.

Analysts still see blockbuster potential for COMP360, with one estimate putting peak sales at $1.9 billion in treatment-resistant depression alone.

The reported Usona filing unsettled investors, and Compass shares fell around 30% after the news before the company announced its application was complete.

Payer coverage and patient access remain key hurdles for Compass, while the FDA’s decisions on both applications could shape how the market develops.

1 source

Related

What people are saying

Stifel analystsAnalysts at Stifel
caught many investors by surprise
via BioPharma Dive
RBC Capital Markets analystsAnalysts at RBC Capital Markets
sufficient room for many new psychedelics
via BioPharma Dive